<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968548</url>
  </required_header>
  <id_info>
    <org_study_id>Lung-RND-003</org_study_id>
    <nct_id>NCT04968548</nct_id>
  </id_info>
  <brief_title>Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening</brief_title>
  <official_title>Determination and Validation of Lung EpiCheckÂ®: A Multianalyte Assay for Lung Cancer Prediction. A Case-Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is part of the development and validation of a non-invasive lung screening test&#xD;
      which aim to identify early stage lung cancer in patients at high risk for lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, case-control, multi-center, observational nonsignificant risk study.&#xD;
      The study aims to collect blood and clinical data from subjects undergoing Low Dose CT (LDCT)&#xD;
      for lung cancer screening and subjects with confirmed lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of blood samples</measure>
    <time_frame>24 Months</time_frame>
    <description>Collect blood to support the development and validation of a multi analyte test for lung cancer screening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical data collection</measure>
    <time_frame>24 Months</time_frame>
    <description>Collect clinical data to support the development and validation of a multi analyte test for lung cancer screening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>36 Months</time_frame>
    <description>Performance of the assay in terms of (1) Sensitivity (2) Specificity (3) NPV (negative predictive value) and (4) PPV (positive predictive value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>36 Months</time_frame>
    <description>Performance of the assay in terms of Sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>36 Months</time_frame>
    <description>Performance of the assay in terms of Specificity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>36 Months</time_frame>
    <description>Performance of the assay in terms of NPV (negative predictive value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>36 Months</time_frame>
    <description>Performance of the assay in terms of PPV (positive predictive value)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cases Series</arm_group_label>
    <description>Subjects with confirmed lung cancer diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening Series</arm_group_label>
    <description>Subjects undergoing LDCT for lung cancer screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Peripheral blood will be collected via routine venipuncture procedure</description>
    <arm_group_label>Cases Series</arm_group_label>
    <arm_group_label>Screening Series</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Case Series will include subjects 50-80 years old, current or past smokers with at&#xD;
        least 20 pack-years, with either (a) a high suspicion for lung cancer, who are planning to&#xD;
        undergo surgery to establish a definitive diagnosis; or (b) confirmed lung cancer&#xD;
        diagnosis, however did not yet undergo any treatment for this cancerous lesion.&#xD;
&#xD;
        The Screening Series will include subjects 50-80 years old, current or past smokers, with&#xD;
        at least 20 pack-years, undergoing LDCT for lung cancer screening.&#xD;
&#xD;
        All subjects should be without other cancer in the past 5 years except for fully resected&#xD;
        non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - Cases:&#xD;
&#xD;
          -  Current or past smokers, with at least 20 pack-years&#xD;
&#xD;
          -  Subjects with either A high suspicion for lung cancer, with planned surgery to&#xD;
             establish a definitive diagnosis within 60 days after date of blood collection OR&#xD;
             treatment naive lung cancer patients&#xD;
&#xD;
        Exclusion Criteria - Cases:&#xD;
&#xD;
          -  Known diagnosis or treatment of any previous cancer, including lung cancer, in the&#xD;
             past 5 years, except for fully resected non-melanoma skin cancer or fully-resected&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Current lung cancer is known to be stage III or IV by pathology.&#xD;
&#xD;
        Inclusion Criteria - Screening:&#xD;
&#xD;
        - Current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer&#xD;
        screening&#xD;
&#xD;
        Exclusion Criteria - Screening:&#xD;
&#xD;
          -  Known diagnosis or treatment of any cancer, including lung cancer, in the past 5&#xD;
             years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  Subjects whose purpose of performing LDCT is for surveillance of a lung nodule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Aharona Shuali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aharona Shuali, MD</last_name>
    <phone>+972-8-9161616</phone>
    <email>aharona@nucleix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lola Fong, MBA</last_name>
    <phone>8582833398</phone>
    <phone_ext>211</phone_ext>
    <email>lola@nucleix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orlando Health, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Edgewood Hospital</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harry S. Truman Memorial Veterans' Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital/The University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaga M, Chorostowska-Wynimko J, HorvÃ¡th I, Tammemagi MC, Shitrit D, Eisenberg VH, Liang H, Stav D, Levy Faber D, Jansen M, Raviv Y, Panagoulias V, Rudzinski P, Izbicki G, Ronen O, Goldhaber A, Moalem R, Arber N, Haas I, Zhou Q. Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals. Eur Respir J. 2021 Jan 14;57(1). pii: 2002682. doi: 10.1183/13993003.02682-2020. Print 2021 Jan.</citation>
    <PMID>33122336</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDCT</keyword>
  <keyword>Low Dose CT</keyword>
  <keyword>Lung Cancer Screening</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>early detection</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

